title: [New approaches for the treatment of superficial bladder cancer].
abstract: Extending up to the submucosa, superficial bladder tumours (pTis, pTa et pTi) are initially treated by transurethral resection. According to their risk of recurrence and progression, this frequent cancer subsequently benefits from intra-vesical instillations of cytotoxic agents and immunomodulators. Several new treatments are currently being evaluated, namely new genetically modified BCG strains, so as novel means to administrate intravesical chemotherapy, which seam to improve prognosis. Owing to the significant prevalence of superficial bladder cancer and its morbidity, these new therapeutic means will probably be increasingly used.
authors.forename: Caroline Carera
authors.initials: CC
authors.lastname: Sager
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Benamran
authors.forename: Gregory
authors.initials: G
authors.lastname: Wirth
authors.forename: Christophe E
authors.initials: CE
authors.lastname: Iselin
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D018450:Disease Progression; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine